Name: Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Diagnosis
Published: 2026-09-14T15:39:06-04:00

Product information and disease description Place of product in therapy Disease description

Diagnosis

6 evidence topics · 6 sources

Serum GM-CSF neutralizing autoantibodies

“Detection of GM-CSF neutralizing autoantibodies in serum confirms autoimmune PAP and rules out other causes.” (opens the source at this quote in a new tab)

Dried blood spot card autoantibody testing

“30 autoimmune PAP patients and 19 healthy people” (opens the source at this quote in a new tab)
“the sensitivity and specificity of the DBSC GMAb test were both 100%” (opens the source at this quote in a new tab)

Immunochromatographic anti-GM-CSF autoantibody testing

“211 APAP and 171 non-APAP cases.” (opens the source at this quote in a new tab)

Exploratory biomarker study population

“Overall, 144 individuals were enrolled” (opens the source at this quote in a new tab)

Diagnostic assay clinical accuracy

“Clinical accuracy achieved 100% in a cohort of 40 subjects that utilized a cut-off value of 8.0 μg/mL” (opens the source at this quote in a new tab)

Diagnostic pathways and delays

“Patients reported heterogeneous and indirect diagnostic pathways, often waiting months or years for the correct diagnosis.” (opens the source at this quote in a new tab)